Muscimol is not considered safe for general use. The FDA has explicitly determined that muscimol, along with Amanita muscaria mushroom extracts, does not meet the standard for safe food ingredients, and products containing it are classified as adulterated under federal law. While muscimol is not as acutely dangerous as many other psychoactive compounds, it carries real risks of neurological side effects, unpredictable dosing, and contamination with a genuinely neurotoxic precursor called ibotenic acid.
What Muscimol Does in Your Brain
Muscimol is the primary psychoactive compound in Amanita muscaria, the red-and-white spotted mushroom sometimes called fly agaric. It works by mimicking GABA, the brain’s main calming neurotransmitter. When muscimol binds to GABA receptors, it amplifies the brain’s inhibitory signaling, producing sedation, altered perception, and muscle relaxation. This mechanism is loosely similar to how benzodiazepines work, but muscimol is far more potent and less targeted. It reduces brain glucose metabolism more aggressively than benzodiazepines, which have a built-in ceiling effect at higher doses. Muscimol does not.
Its effects peak around three hours after ingestion. The compound is metabolized and cleared from the body relatively quickly, which reduces the risk of accumulation with repeated exposure. However, a short half-life does not equal safety. Because muscimol activates GABA receptors throughout the brain rather than in specific regions, it has a broad and somewhat unpredictable range of effects depending on the dose, the individual, and what else is in the product.
The Ibotenic Acid Problem
One of the biggest safety concerns with muscimol isn’t muscimol itself. It’s ibotenic acid, the compound that naturally occurs alongside muscimol in Amanita muscaria and converts into muscimol through a chemical process called decarboxylation. Ibotenic acid is structurally similar to glutamate, an excitatory brain chemical, and it crosses the blood-brain barrier easily. Once there, it overstimulates neurons. It is classified as a neurotoxin.
People who ingest ibotenic acid can experience hallucinations, seizures, loss of coordination, confusion, anxiety, and alternating waves of euphoria and agitation. Animal studies show it significantly disrupts neurotransmitter levels, particularly reducing glutamic acid concentrations in the hippocampus and brain stem. The dose needed to cause psychoactive effects from ibotenic acid is roughly 30 to 60 mg, which is five to ten times higher than the 6 mg psychoactive threshold for muscimol. But in raw or improperly prepared mushrooms, ibotenic acid can be present in substantial amounts.
Manufacturers of Amanita muscaria extracts attempt to convert ibotenic acid into muscimol through controlled decarboxylation, but the completeness of that conversion varies widely. There is no standardized process, no regulatory oversight of the conversion, and no required testing to verify how much ibotenic acid remains in a finished product. This means any product derived from Amanita muscaria could contain an unknown amount of a known neurotoxin.
Known Side Effects and Overdose Risks
Even when muscimol is relatively pure, it produces a range of adverse effects. A CDC report on patients who consumed Amanita muscaria gummies documented tachycardia (elevated heart rate), confusion, anxiety or excessive drowsiness, nausea, hallucinations, and altered mental status. One patient reported chest pain. These were not people who consumed enormous quantities. They were using commercially available gummy products.
The margin between a dose that produces psychoactive effects and a dose that causes neurological harm is narrow. According to FDA data, the median dose at which muscimol becomes neurotoxic in animal models is just 0.65 mg per kilogram of body weight. For a 70 kg (154 lb) person, that translates to roughly 45 mg. The psychoactive threshold sits around 6 mg. The median lethal dose in animal models is 8.1 mg per kilogram, or about 567 mg for the same person. That sounds like a wide gap, but in practice, the neurotoxic threshold is only about seven times the psychoactive dose, leaving very little room for error in an unregulated product with inconsistent potency.
Common side effects at lower doses include:
- Sedation and drowsiness, sometimes deep enough to impair responsiveness
- Ataxia, or loss of muscle coordination, which increases fall and injury risk
- Gastrointestinal distress, including nausea and vomiting
- Confusion and disorientation, which can last several hours
- Hallucinations, particularly at moderate to high doses
FDA Regulatory Status
The FDA issued a formal letter to industry in 2024 stating that Amanita muscaria, its extracts, and its constituents (muscimol, ibotenic acid, and muscarine) are unapproved food additives. They do not meet the Generally Recognized as Safe (GRAS) standard. Any conventional food product containing these ingredients is considered adulterated under federal law and subject to enforcement action.
The FDA’s safety standard requires “a reasonable certainty in the minds of competent scientists that no harm would result from the intended use of the substance.” Muscimol does not meet that bar. Despite this, Amanita muscaria gummies, tinctures, and capsules remain widely available online and in retail stores, often marketed as nootropics or sleep aids. The CDC has flagged that some of these products have been found to contain Schedule I substances not listed on the label.
Why Dosing Is Unreliable
People who use Amanita muscaria products sometimes follow a “microdosing” approach, using small amounts of dried mushroom (typically under 0.5 grams) to stay below the psychoactive threshold. The problem is that muscimol and ibotenic acid content varies enormously between individual mushrooms, between batches, and between growing regions. Two caps from the same forest can differ in potency by several fold.
Commercial products introduce additional uncertainty. Without standardized manufacturing processes or required third-party testing, the labeled dose on a gummy or capsule may bear little relationship to what’s actually inside. The CDC investigation found undisclosed controlled substances in some Amanita muscaria gummy products, highlighting how loosely regulated this market is.
Limited Data on Long-Term Use
There are no human clinical trials evaluating the long-term safety of muscimol. Most of what is known comes from animal studies and case reports of poisoning. A systematic review of preclinical research noted that muscimol’s broad receptor activity throughout the brain creates liability for adverse effects, even though its short half-life reduces accumulation risk. Whether repeated use causes lasting changes to GABA receptor sensitivity, tolerance, or withdrawal symptoms in humans remains unstudied. The absence of evidence here is not reassuring. It simply means no one has done the work to find out.
Researchers have explored muscimol’s potential for treating neuropathic pain in animal models, and some manufacturers market Amanita muscaria products for stress, pain, and sleep. But potential therapeutic applications and consumer safety are very different questions. Pharmaceutical development involves isolating a compound, establishing precise dosing, characterizing side effects in controlled trials, and manufacturing under strict quality standards. None of that infrastructure exists for muscimol products currently on the market.